Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study ; volume:20 ; number:1 ; day:7 ; month:8 ; year:2018 ; pages:1-9 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (7.8.2018), 1-9, 12.2018
- Urheber
-
Lee, Joshua L.
- Beteiligte Personen und Organisationen
-
Sinnathurai, Premarani
Buchbinder, Rachelle
Hill, Catherine
Lassere, Marissa
March, Lyn
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1669-x
- URN
-
urn:nbn:de:101:1-2018100722102159141737
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Joshua L.
- Sinnathurai, Premarani
- Buchbinder, Rachelle
- Hill, Catherine
- Lassere, Marissa
- March, Lyn
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biologics, cardiovascular effects and cancer
P11.24: Rheumatoid Arthritis and Cardiovascular Events
Editorial: Methods in cardiovascular biologics and regenerative medicine
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Real-world retention rates of biologics in patients with rheumatoid arthritis
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study
Biologics, cardiovascular effects and cancer
P11.24: Rheumatoid Arthritis and Cardiovascular Events
Editorial: Methods in cardiovascular biologics and regenerative medicine
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Real-world retention rates of biologics in patients with rheumatoid arthritis
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
Features and Outcomes of Microcrystalline Arthritis Treated by Biologics: A Retrospective Study
Biologics, cardiovascular effects and cancer
P11.24: Rheumatoid Arthritis and Cardiovascular Events
Editorial: Methods in cardiovascular biologics and regenerative medicine
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Treatment persistence of biologics among patients with psoriatic arthritis
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Similar risk of cardiovascular events in idiopathic inflammatory myopathy and rheumatoid arthritis in the first 5 years after diagnosis
Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
Real-world retention rates of biologics in patients with rheumatoid arthritis
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review